December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

17.23 +0.54 (+3.24%)
Streaming Delayed Price Updated: 1:23 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The... 
Via StockStory
Topics Stocks
News headline image
Amneal to Report Second Quarter 2026 Results on July 30, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mooning Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
3 Russell 2000 Stocks with Open Questions
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics... 
Via MarketBeat
News headline image
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Why Amneal (AMRX) Stock Is Trading Up Today
What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini... 
Via StockStory
News headline image
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Profitable Stocks with Open Questions
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Topics Economy
News headline image
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 Reasons AMRX is Risky and 1 Stock to Buy Instead
Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Amneal Reports First Quarter 2026 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amneal (AMRX) Q2 2025 Earnings Transcript ↗
Amneal (AMRX) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain
News headline image
1 Value Stock to Target This Week and 2 Facing Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
Amneal (AMRX) Q1 2026 Earnings Transcript ↗
Amneal (AMRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ... 
Via StockStory
News headline image
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ... 
Via StockStory
Topics Economy
News headline image
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
2 Cash-Producing Stocks to Research Further and 1 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 of Wall Street’s Favorite Stocks We Steer Clear Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
Amneal to Report First Quarter 2026 Results on May 1, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.